SynthesisBrain and behavior2021
A systematic review of myasthenia gravis complicated with myocarditis.
Synthesis in Brain and behavior, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Exploring the role of immune checkpoint inhibitors in the etiology of myasthenia gravis and Lambert-Eaton myasthenic syndrome: A systematic review.Frontiers in neurology · 2022Pooled it
- A systematic review of myasthenia gravis complicated with myocarditis.Brain and behavior · 2021Pooled it
- Comorbidities and Treatment Patterns in People With Myasthenia Gravis in Denmark, Finland and Sweden: A Population-Based Observational Study.Muscle & nerve · 2026Observational
- Case report: Efgartigimod combined with intravenous methylprednisolone in a case of co-occurrence of unexplained myasthenia gravis, inflammatory myopathy, and fulminant myocarditis.Frontiers in immunology · 2026Article
- Case Report: Thymoma-associated myasthenia gravis, myositis, myocarditis, and anti-GAD65 autoimmune encephalitis: a unique case of paraneoplastic polyautoimmunity.Frontiers in immunology · 2026Article
- Beyond the Surface: Investigating the Potential Mechanisms of Non-Motor Symptoms in Myasthenia Gravis.European journal of neurology · 2025Review
- Thymoma-Induced Severe Biventricular Failure without Myasthenia Gravis: Investigating Tachycardia-Induced Cardiomyopathy.The American journal of case reports · 2025Article
- Article
- Case Report: Immune checkpoint inhibitor-associated myocarditis in an esophageal cancer patient with myasthenia gravis following combined radiotherapy and immunotherapy.Frontiers in oncology · 2025Article
- Cardiac implications in myasthenia gravis.World journal of clinical cases · 2024Article
- Article
- Myasthenia gravis, respiratory function, and respiratory tract disease.Journal of neurology · 2023Review
- Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis.Annals of the rheumatic diseases · 2023Article
- Anti-titin antibodies are associated with myocarditis in patients with myasthenia gravis.Journal of neurology · 2023Article
- Two Cases of Immune Checkpoint Inhibitor-Induced Myocarditis With Complete Atrioventricular Block.Cureus · 2023Article
- Myocardial Injury in Hospitalized Patients with Myasthenia Gravis.Journal of clinical medicine · 2022Article
- Nivolumab-induced Myositis and Myocarditis with Positive Anti-titin Antibody and Anti-voltage-gated Potassium Channel Kv1.4 Antibody.Internal medicine (Tokyo, Japan) · 2022Article
- Role of Endomyocardial Biopsy in Diagnostics of Myocarditis.Diagnostics (Basel, Switzerland) · 2022Review
- Neurological Manifestations of Myocarditis.Current neurology and neuroscience reports · 2022Review
- Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Among many of the autoimmune diseases observed in patients with myasthenia gravis (MG), myocarditis is one of the most critical. The goal of this review is to systematically describe and investigate the characteristics of MG complicated with myocarditis. We identified 183 records in PubMed (MEDLINE), Web of Science, and EMBASE from 1948 to September 10, 2020. Studies were included if they presented clinical data on MG complicated with myocarditis. Of the 35 patients from 28 studies in this review, 57.14% (20/35) were males, with a mean age of 59.11 ± 15.87. Dyspnea was the most common cardiac symptom accounting for over 60% in the study. Among the 35 patients, 13 cases of myocarditis occurred concomitantly with MG and the longest interval between MG and myocarditis was 7 years. Forty percent of patients developed myocarditis caused by immune checkpoint inhibitors (ICI). Among the patients with myocarditis, over half of the patients were diagnosed by myocardial biopsy. After active immune regulation and symptomatic treatment, only 15 of 35 patients with MG complicated with myocarditis improved, 18 patients died during hospitalization, one patient died due to tumor progression and 1patient died 5 years later. The prognosis of patients with MG complicated with myocarditis is poor, and myocardial enzymes and other indexes need to be monitored for patients taking ICI drugs. Patients with dyspnea who are still not ideally treated by mechanical ventilation should be vigilant against the occurrence of MG complicated with myocarditis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.